Elutia Posts Narrower Loss in Fiscal Q2

Elutia (NASDAQ:ELUT), a medical technology company specializing in biologic products for device protection and surgical reconstruction, released its second-quarter earnings on August 14, 2025, reporting results for the period ended June 30. The company saw its bottom-line loss per share narrow compared to the same period last year, but operating losses increased due to higher litigation expenses. Revenue came in at $6.26 million, just below the analyst consensus of $6.55 million, and was nearly unchanged from the prior year. The quarter reflected a mix of progress and ongoing challenges, with notable growth in EluPro and margin gains, while declines in other product lines and persistent losses highlighted areas for improvement. Source: Analyst estimates provided by FactSet. Elutia develops biologic-based medical products that protect implantable devices from infection and support soft-tissue reconstruction. Its main revenue drivers are device protection products, such as the BioEnvelope family, and regenerative matrices for women’s health and soft tissue repair.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool